Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
22 07 2021
Historique:
pubmed: 14 7 2021
medline: 7 10 2021
entrez: 13 7 2021
Statut: ppublish

Résumé

Constitutive activation of the canonical Wnt signaling pathway, in most cases driven by inactivation of the tumor suppressor APC, is a hallmark of colorectal cancer. Tankyrases are druggable key regulators in these malignancies and are considered as attractive targets for therapeutic interventions, although no inhibitor has been progressed to clinical development yet. We continued our efforts to develop tankyrase inhibitors targeting the nicotinamide pocket with suitable drug-like properties for investigating effects of Wnt pathway inhibition on tumor growth. Herein, the identification of a screening hit series and its optimization through scaffold hopping and SAR exploration is described. The systematic assessment delivered

Identifiants

pubmed: 34255518
doi: 10.1021/acs.jmedchem.1c00800
doi:

Substances chimiques

Antineoplastic Agents 0
Enzyme Inhibitors 0
Tankyrases EC 2.4.2.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10371-10392

Auteurs

Hans-Peter Buchstaller (HP)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Uwe Anlauf (U)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Dieter Dorsch (D)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Sarah Kögler (S)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Daniel Kuhn (D)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Martin Lehmann (M)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Birgitta Leuthner (B)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Sara Lodholz (S)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Djordje Musil (D)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Daniela Radtki (D)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Corinna Rettig (C)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Claudio Ritzert (C)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Felix Rohdich (F)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Richard Schneider (R)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Ansgar Wegener (A)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Stefan Weigt (S)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Kai Wilkinson (K)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Christina Esdar (C)

Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH